98O The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumour infiltrating lymphocytes (sTIL)
Titel:
98O The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumour infiltrating lymphocytes (sTIL)
Auteur:
Abuhadra, N. Sun, R. Litton, J.K. Rauch, G. Thompson, A.M. Lim, B. Adrada, B. Mittendorf, E. Damodaran, S. Pitpitan, R. Arun, B. White, J. Ravenberg, E. Santiago, L. Sahin, A. Murthy, R. Ueno, N.T. Ibrahim, N. Moulder, S. Huo, L.